دورية أكاديمية
Heart rate reactivity, recovery, and endurance of the incremental shuttle walk test in patients prone to heart failure.
| العنوان: | Heart rate reactivity, recovery, and endurance of the incremental shuttle walk test in patients prone to heart failure. |
|---|---|
| المؤلفون: | Wei FF; Department of Cardiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.; Non-Profit Research Association Alliance for the Promotion of Preventive Medicine (APPREMED), Mechelen, Belgium., Mariottoni B; Department of Cardiology, Cortona Hospital, Arezzo, Italy., An DW; Non-Profit Research Association Alliance for the Promotion of Preventive Medicine (APPREMED), Mechelen, Belgium.; Department of Cardiovascular Medicine, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, State Key Laboratory of Medical Genomics, National Research Centre for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China., Pellicori P; British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK., Yu YL; Non-Profit Research Association Alliance for the Promotion of Preventive Medicine (APPREMED), Mechelen, Belgium.; Research Unit Environment and Health, KU Leuven Department of Public Health and Primary Care, University of Leuven, Leuven, Belgium., Verdonschot JAJ; Department of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands., Liu C; Department of Cardiology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China., Ahmed FZ; Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK., Petutschnigg J; Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité University Medicine Berlin, Berlin Institute of Health and German Center for Cardiovascular Research, Partner Site Berlin, Berlin, Germany., Rossignol P; Université de Lorraine, Inserm, Centre d'Investigation Clinique Plurithématique 1433, U1116, CHRU de Nancy, F-CRIN INI-CRCT, Nancy, France., Heymans S; Department of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands., Cuthbert J; Department of Cardiology, Castle Hill Hospital, University of Hull, Cottingham, UK., Girerd N; Université de Lorraine, Inserm, Centre d'Investigation Clinique Plurithématique 1433, U1116, CHRU de Nancy, F-CRIN INI-CRCT, Nancy, France., Li Y; Department of Cardiovascular Medicine, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, State Key Laboratory of Medical Genomics, National Research Centre for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China., Clark AL; Department of Cardiology, Castle Hill Hospital, University of Hull, Cottingham, UK., Nawrot TS; Research Unit Environment and Health, KU Leuven Department of Public Health and Primary Care, University of Leuven, Leuven, Belgium.; Centre for Environmental Sciences, Hasselt University, Hasselt, Belgium., Ferreira JP; Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto, Porto, Portugal.; Portugal Heart Failure Clinics, Department of Internal Medicine, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal., Zannad F; Université de Lorraine, Inserm, Centre d'Investigation Clinique Plurithématique 1433, U1116, CHRU de Nancy, F-CRIN INI-CRCT, Nancy, France., Cleland JGF; British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK., Staessen JA; Non-Profit Research Association Alliance for the Promotion of Preventive Medicine (APPREMED), Mechelen, Belgium.; Department of Cardiovascular Medicine, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, State Key Laboratory of Medical Genomics, National Research Centre for Translational Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.; Biomedical Science Group, University of Leuven, Leuven, Belgium. |
| مؤلفون مشاركون: | HOMAGE investigators |
| المصدر: | ESC heart failure [ESC Heart Fail] 2024 Aug 11. Date of Electronic Publication: 2024 Aug 11. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: John Wiley & Sons Ltd on behalf of the European Society of Cardiology Country of Publication: England NLM ID: 101669191 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2055-5822 (Electronic) Linking ISSN: 20555822 NLM ISO Abbreviation: ESC Heart Fail Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Oxford] : John Wiley & Sons Ltd on behalf of the European Society of Cardiology, [2014]- |
| مستخلص: | Aims: Few randomized trials assessed the changes over time in the chronotropic heart rate (HR) reactivity (CHR), HR recovery (HRR) and exercise endurance (EE) in response to the incremental shuttle walk test (ISWT). We addressed this issue by analysing the open HOMAGE (Heart OMics in Aging) trial. Methods: In HOMAGE, 527 patients prone to heart failure were randomized to usual treatment with or without spironolactone (25-50 mg/day). The current sub-study included 113 controls and 114 patients assigned spironolactone (~70% on beta-blockers), who all completed the ISWT at baseline and at Months 1 and 9. Within-group changes over time (follow-up minus baseline) and between-group differences at each time point (spironolactone minus control) were analysed by repeated measures ANOVA, unadjusted or adjusted for sex, age and body mass index, and additionally for baseline for testing 1 and 9 month data. Results: Irrespective of randomization, the resting HR and CHR did not change from baseline to follow-up, with the exception of a small decrease in the HR immediately post-exercise (-3.11 b.p.m.) in controls at Month 9. In within-group analyses, HR decline over the 5 min post-exercise followed a slightly lower course at the 1 month visit in controls and at the 9 month visits in both groups, but not at the 1 month visit in the spironolactone group. Compared with baseline, EE increased by two to three shuttles at Months 1 and 9 in the spironolactone group but remained unchanged in the control group. In the between-group analyses, irrespective of adjustment, there were no HR differences at any time point from rest up to 5 min post-exercise or in EE. Subgroup analyses by sex or categorized by the medians of age, left ventricular ejection fraction or glomerular filtration rate were confirmatory. Combining baseline and Months 1 and 9 data in both treatment groups, the resting HR, CHR and HRR at 1 and 5 min averaged 61.5, 20.0, 9.07 and 13.8 b.p.m. and EE 48.3 shuttles. Conclusions: Spironolactone on top of usual treatment compared with usual treatment alone did not change resting HR, CHR, HRR and EE in response to ISWT. Beta-blockade might have concealed the effects of spironolactone. The current findings demonstrate that the ISWT, already used in a wide variety of pathological conditions, is a practical instrument to measure symptom-limited exercise capacity in patients prone to developing heart failure because of coronary heart disease. (© 2024 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.) |
| References: | von Haehling S, Arzt M, Doehner W, Edelmann F, Evertz R, Ebner N, et al. Improving exercise capacity and quality of life using non‐invasive heart failure treatments: Evidence from clinical trials. Eur J Heart Fail 2021;23:92‐113. doi:10.1002/ejhf.1838. Singh R, Aggarwal D, Dutta K, Jaggi S, Sodhi MK, Saini V. Assessment of the feasibility of 1‐min sit‐to‐stand test in evaluating functional exercise capacity in interstitial lung disease patients. J Exerc Rehabil. 2023;19:363‐369. doi:10.12965/jer.2346418.209. Nishiyama Y, Morita H, Harada H, Katoh A, Adachi H, Koga A, et al. Systolic blood pressure to exercise as predictor of mortality in patients with chronic heart failure. Int Heart J 2010;51:111‐115. doi:10.1536/ihj.51.111. Carneiro HA, Song RJ, Lee J, Schwartz B, Vasan RS, Xanthakis V. Association of blood pressure and heart rate responses to submaximal exercise with incident heart failure: The Framingham Heart Study. J Am Heart Assoc 2021;10:e019460. doi:10.1161/JAHA.120.019460. Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, et al. Clinician's guide to cardiopulmonary exercise testing in adults: A scientific statement from the American Heart Association. Circulation 2010;122:191‐225. doi:10.1161/CIR.0b013e3181e52e69. Pulz C, Diniz RV, Alves ANF, Tebexreni AS, Carvalho AC, de Paola ÂAV, et al. Incremental shuttle and six‐minute walking tests in the assessment of the functional capacity in chronic heart failure. Can J Cardiol 2008;24:131‐135. doi:10.1016/s0828‐282x(08)70569‐5. Lim HJ, Jee SJ, Lee MM. Comparison of incremental shuttle walk test, 6‐minute walking test, and cardiopulmonary exercise stress test in patients with myocardial infarction. Med Sci Monit 2024;28:e938140. doi:10.12659/MSM.938140. Girotra S, Kitzman DW, Kop WJ, Stein PK, Gottdiener JS, Mukamal KJ. Heart rate response to a timed walk and cardiovascular outcomes in older adults: The Cardiovascular Health Study. Cardiology 2012;122:69‐75. doi:10.1159/000338736. Georgiopoulou VV, Kalogeropoulos A, Chowdhury R, Binongo JNG, Bibbins‐Domingo K, Rodondi N, et al. Exercise capacity, heart failure risk, and mortality in older adults: The Health ABC Study. Am J Prev Med 2017;52:144‐153. doi:10.1016/j.amepre.2016.08.041. Oppewal A, Hilgenkamp TIM, van Wijck R, Evenhuis HM. Heart rate recovery after the 10‐m incremental shuttle walking test in older adults with intellectual disabilities. Res Dev Disabil 2014;35:696‐704. doi:10.1016/j.ridd.2013.12.006. Billings CG, Hurdman JA, Condliffe R, Elliot CA, Smith IA, Austin M, et al. Incremental shuttle walk test distance and autonomic dysfunction predict survival in pulmonary arterial hypertension. J Heart Lung Transplant 2017;36:871‐879. doi:10.1016/j.healun.2017.04.008. Marsico A, Dal Corso S, De Carvalho EF, Arakelian V, Phillips S, Stirbulov R, et al. A more effective alternative to the 6‐minute walk test for the assessment of functional capacity in patients with pulmonary hypertension. Eur J Phys Rehabil Med 2021;57:645‐652. doi:10.23736/S1973‐9087.21.06561‐8. Minai OA, Nguyen Q, Mummadi S, Walker E, McCarthy K, Dweik RA. Heart rate recovery is an important predictor of outcomes in patients with connective tissue‐associated pulmonary hypertension. Pulm Circ 2015;5:565‐576. doi:10.1086/682432. Chen SY, Huang CK, Wu CL, Peng HC, Yu CJ, Chien JY. Prognostic value of the post‐exercise heart rate recovery and BHDE‐index in chronic obstructive pulmonary disease. BMC Pulm Med 2023;23:263. doi:10.1186/s12890‐023‐02557‐7. Zhao D, Abbasi A, Casaburi R, Adami A, Tiller NB, Yuan W, et al. Identifying a heart rate recovery criterion after a 6‐minute walk test in COPD. Int J Chron Obstruct Pulmon Dis 2021;16:2545‐2560. doi:10.2147/COPD.S311572. Fermont JM, Masconi KL, Jensen MT, Ferrari R, Di Lorenzo VAP, Marott JM, et al. Biomarkers and clinical outcomes in COPD: A systematic review and meta‐analysis. Thorax 2024;74:439‐446. doi:10.1136/thoraxjnl‐2018‐211855. Imamuras S, Inagaki T, Abe M, Terada J, Kawasaki T, Nagashima K, et al. Impaired dynamic response of oxygen saturation during the 6‐min walk test is associated with mortality in chronic fibrosing interstitial pneumonia. Respir Care 2023;68:356‐365. doi:10.4187/respcare.10231. Swigris JJ, Swick J, Wamboldt FS, Sprunger D, du Bois R, Fischer A, et al. Heart rate recovery after 6‐min walk test predicts survival in patients with idiopathic pulmonary fibrosis. Chest 2009;136:841‐848. doi:10.1378/chest.09‐0211. Voorn MJJ, Franssen RFW, Verlinden JMWF, Bootsma GP, de Ruysscher K, Bongers BC, et al. Associations between pretreatment physical performance tests and treatment complications in patients with non‐small cell lung cancer: A systematic review. Crit Rev Oncol Hematol 2021;158:103207. doi:10.1016/j.critrevonc.2020.103207. Ha D, Choi H, Zell K, Raymond DP, Stephans K, Wang XF, et al. Association of impaired heart rate recovery with cardiopulmonary complications after lung cancer surgery. J Thorac Cardiovasc Surg 2015;149:1168‐1173. doi:10.1016/j.jtcvs.2014.11.037. Argillander TE, Heil TC, Meils RJF, van Duijvendijk P, Klaase JM, van Munster BC. Preoperative physical performance as predictor of postoperative outcomes in patients aged 65 and older scheduled for major abdominal cancer surgery. Eur J Surg Oncol 2022;48:570‐581. doi:10.1016/j.ejso.2021.09.019. Zweerink A, van der Lingen ALCJ, Handoko ML, van Rossum AC, Allaart CP. Chronotropic incompetence in chronic heart failure: A state‐of‐the‐art review. Circ Heart Fail 2018;11:e004969. doi:10.1161/CIRCHEARTFAILURE.118.004969. Cahalin LP, Forman DE, Chase P, Guazzi M, Myers J, Bensimhon D, et al. The prognostic significance of heart rate recovery is not dependent upon maximal effort in patients with heart failure. Int J Cardiol 2013;168:1496‐1501. doi:10.1016/j.ijcard.2012.12.102. Ferreira JP, Metra M, Anker SD, Dickstein K, Lang CC, Ng L, et al. Clinical correlates and outcome associated with changes in 6‐minute walking distance in patients with heart failure: Findings from the BIOSTAT‐CHF study. Eur J Heart Fail 2019;21:218‐226. doi:10.1002/ejhf.1380. Watson EL, Major RW, Wilkinson TJ, Greening NJ, Gould DW, Barratt J, et al. The association of muscle size, strength and exercise capacity with all‐cause mortality in non‐dialysis‐dependent CKD patients. Clin Physiol Funct Imaging 2020;40:399‐406. doi:10.1111/cpf.12655. Johnson NP, Goldberger JJ. Prognostic value of late heart rate recovery after treadmill exercise. Am J Cardiol 2012;110:45‐49. doi:10.1016/j.amjcard.2012.02.046. Messinger‐Rapport B, Snader CEP, Blackstone EH, Yu D, Lauer MS. Value of exercise capacity and heart rate recovery in older people. J Am Geriatr Soc 2003;51:63‐68. doi:10.1034/j.1601‐5215.2002.51011.x. Cleland JGF, Ferreira JP, Mariottoni B, Pellicori P, Cuthbert J, Verdonschot JAJ, et al. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: The heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial. Eur Heart J 2021;42:684‐696. doi:10.1093/eurheartj/ehaa758. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604‐612. doi:10.7326/0003‐4819‐150‐9‐200905050‐00006. Okutucu S, Ugur N, Aytemir K, Oto A. Heart rate recovery: A practical clinical indicator of abnormal cardiac autonomic function. Exper Rev Cardiovasc Ther 2011;9:1417‐1430. doi:10.1586/erc.11.149. Lu L, Shara N, North East SAS Users Group Conference (NESUG). Reliability analysis: Calculate and comparing intra‐class correlation coefficients (ICC) in SAS. 2007. https://www.lexjansen.com/nesug/nesug07/sa/sa13.pdf. Accessed 08 April 2024. Nishime EO, Cole CR, Blackstone EH, Pashkow FJ, Lauer MS. Heart rate recovery and treadmill exercise score as predictors of mortality in patients referred for exercise ECG. JAMA 2000;284:1392‐1398. doi:10.1001/jama.284.11.1392. Vivekananthan DP, Blackstone EH, Pothier CE, Lauer MS. Heart rate recovery after exercise is a predictor of mortality, independent of the angiographic severity of coronary disease. J Am Coll Cardiol 2003;42:831‐838. doi:10.1016/S0735‐1097(03)00833‐7. Gera N, Taillon LA, Ward RP. Usefulness of abnormal heart rate recovery on exercise stress testing predicts high‐risk findings on single‐photon emission computed tomography myocardial perfusion imaging in men. Am J Cardiol 2009;103:611‐614. doi:10.1016/j.amjcard.2008.11.004. Ghaffari S, Kazemi B, Aliakbarzadeh P. Abnormal heart rate recovery after exercise predicts coronary artery disease severity. Cardiol J 2011;18:47‐54. Chen MS, Blackstone EH, Pothier CE, Lauer MS. Heart rate recovery and impact of myocardial revascularization on long‐term mortality. Circulation 2004;110:2851‐2857. doi:10.1161/01.CIR.0000147539.39775.F4. Yawn BP, Ammar KA, Thomas R, Wollan PC. Test retest reproducibility of heart rate recovery after treadmill exercise. Ann Fam Med 2003;1:236‐241. doi:10.1370/afm.37. Tulumen E, Khalilayeva I, Aytemir K, Kaya EB, Deveci OS, Aksoy H, et al. The reproducibility of heart rate recovery after treadmill exercise. Ann Noninvasive Electrocardiol 2021;16:365‐372. doi:10.1111/j.1542‐474X.2011.00464.x. Huang J, Yu Z, Wu Y, He X, Zhao J, He J, et al. Prognostic significance of blood pressure at rest and after performing the six‐minute walk test in patients with acute heart failure. Am J Hypertens 2023;37:199‐206. doi:10.1093//ajh/hpad115. Olsson LG, Swedberg K, Clark AL, Witte KK, Cleland JGF. Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: A systematic review. Eur Heart J 2005;26:778‐793. doi:10.1093/eurheartj/ehi162. Morales FJ, Montemayor T, Martinez A. Shuttle versus six‐minute walk test in the prediction of outcome in chronic heart failure. Int J Cardiol 2000;76:101‐105. doi:10.1016/s0167‐5273(00)00393‐4. Parreira VF, Janaudis‐Ferreira T, Evans RA, Mathur S, Goldstein RS, Brooks D. Measurement properties of the incremental shuttle walk test: A systematic review. Chest 2014;145:1357‐1369. doi:10.1378/chest.13‐2071. Singh SJ, Jones PW, Evans R, Morgan MDL. Minimum clinically improvement for the incremental shuttle walking test. Thorax 2008;63:775‐777. doi:10.1136/thx.2007.081208. Malkin CJ, Pugh PJ, West JN, van Beek EJR, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: A double‐blind randomized placebo controlled trial. Eur Heart J 2006;27:57‐64. doi:10.1093/eurheartj/ehi443. Burton LA, Sumukadas D, Witham MD, Struthers AD, McMurdo MET. Effect of spironolactone on physical performance in older people with self‐reported physical disability. Am J Med 2013;126:590‐597. doi:10.1016/j.amjmed.2012.11.032. Edelmann F, Wachter R, Schmidt AG, Kraigher‐Krainer E, Colantonio C, Kamke W, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction. The Aldo‐HF randomized controlled clinical trial. JAMA 2013;309:781‐791. doi:10.1001/jama.2013.905. Kosmala W, Rojek M, Przewlocka‐Kosmala M, Wright L, Mysiak A, Marwick TH. Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction. J Am Coll Cardiol 2016;68:1823‐1834. doi:10.1016/j.jacc.2016.07.763. Jackson G, Atkinson L, Oram S. Reassessment of failed beta‐blocker treatment in angina pectoris by peak‐exercise heart rate measurements. Br Med J 1975;3:616‐618. doi:10.1136/bmj.3.5984.616. Nyberg G. Effect of beta‐adrenoceptor blockers on heart rate and blood pressure in dynamic and isometric exercise. Drugs 1976;11:185‐195. doi:10.2165/00003495‐197600111‐00037. |
| معلومات مُعتمدة: | European Union Seventh Framework Program; OMRON Healthcare, Co., Ltd. |
| فهرسة مساهمة: | Keywords: heart failure; heart rate; incremental shuttle walk test; mineralocorticoid receptor antagonism; spironolactone |
| تواريخ الأحداث: | Date Created: 20240811 Latest Revision: 20240811 |
| رمز التحديث: | 20240813 |
| DOI: | 10.1002/ehf2.15000 |
| PMID: | 39129059 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2055-5822 |
|---|---|
| DOI: | 10.1002/ehf2.15000 |